NCT04699747招募中1 期
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Binding of 18-F 3F4AP in the brain of healthy volunteers and multiple sclerosis subjects
研究概览
简要总结
Our overall objective is to obtain an initial assessment of the potential value of using [18F]3F4AP for imaging demyelinating diseases such as multiple sclerosis:
- Aim 1) Assess the safety of [18F]3F4AP in healthy volunteers and subjects with multiple sclerosis (MS). Hypothesis 1: Administration of [18F]3F4AP will result in no changes in vitals or other adverse events.
- Aim 2) Assess the pharmacokinetics of a bolus infusion of [18F]3F4AP in humans including healthy volunteers and MS patients. Hypothesis 2: the pharmacokinetics of [18F]3F4AP at the whole brain level will be similar in controls and MS subjects. The kinetics in demyelinated lesions will be slower than in healthy control areas.
- Aim 3) Assess the reproducibility of [18F]3F4AP in humans. Hypothesis 3: the test/retest variability of [18F]3F4AP within the same subject will be lower than 10%.
- Aim 4) Correlate MR brain images with [18F]3F4AP PET brain images. Hypothesis 4A: all the lesions seen on the MRI will show increased signal (VT or SUV) on the PET images. Hypothesis 4B: some of the lesions on the MRI will show increased signal (VT or SUV) on the PET but not all.
- Aim 5) Correlate [18F]3F4AP PET signal with neuropsychological testing in people with MS. Hypothesis 5: increased PET signal (VT or SUV) will correlate with impaired Single Digit Modality Test (SDMT) scores.
- Aim 6) Correlate [18F]3F4AP PET signal with EDSS score in people with MS. Hypothesis 6: increased PET signal (VT or SUV) will correlate with higher EDSS scores.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must be ≥18 and <65 years of age;
- •Able to understand and provide informed consent prior to study procedures
排除标准
- •Subjects with known structural brain disease (e.g. brain tumor or stroke);
- •Any contraindication to MRI and/or PET, including:
- •Subjects with life vest;
- •Subjects with implanted heart device (e.g. ICD, Pacemaker);
- •Subjects with metallic fragment or foreign body;
- •Subjects with other form of devices or prosthesis that are not MRI compatible, such as insulin pump, joint replacement, hearing aid, cochlear implant, permanent contraceptive devices, etc.;
- •Subjects with severe claustrophobia
- •Relative or absolute contraindication to Dotarem contrast:
- •history of renal disease including acute or chronic severe renal insufficiency (glomerular filtration rate <60 mL/min/1.73m2);
- •history of diabetes mellitus, systemic lupus, multiple myeloma, nephrogenic systemic fibrosis, and other co-morbidities;
- •History of hypersensitive reactions to Dotarem and/or gadolinium contrast agent;
- •Radiation exposure exceeds current Radiology Department guidelines (i.e., 50 mSv in the prior 12 months);
- •Female subjects only: Positive serum pregnancy test, or lactating, or possibility of pregnancy cannot be ruled out prior to dosing;
- •Inability to provide written informed consent;
- •Any clinically significant acute or unstable physical or psychiatric condition, judged by the investigators based on medical history or screening physical examination, to be incompatible with the study;
- •Any physical or psychiatric condition judged by the investigators to be incompatible with the study, based on medical history or screening physical examination;
- •Abnormal results on blood tests judged by the investigators to be incompatible with the study.
研究组 & 干预措施
Multiple sclerosis
Experimental
F-18 3F4AP PET Scan
干预措施: F-18 3F4AP (Drug)
Healthy controls
Active Comparator
F-18 3F4AP PET Scan
干预措施: F-18 3F4AP (Drug)
结局指标
主要结局
Binding of 18-F 3F4AP in the brain of healthy volunteers and multiple sclerosis subjects
时间窗: Baseline
Binding of the tracer will be quantified using volumes of distribution (VTs). Volume of distribution is the ratio of tracer concentration in tissue to plasma at equilibrium and will be determined using standard pharmacokinetic methods (Innis et al, J Cereb Blood Flow Metab. 2007; 27(9): 1533-1539).
Number of participants with adverse events related to tracer administration as assessed by CTCAE v4.0
时间窗: 5 years
Determine number of participants adverse events related to tracer administration as assessed by CTCAE v4.0
次要结局
- Binding of 18-F 3F4AP in brain lesions of multiple sclerosis subjects(Baseline)
- Within-subject variability in healthy controls and multiple sclerosis subjects(Retest within 3 months of baseline)
研究者
Pedro Brugarolas
Assistant Professor of Radiology
Massachusetts General Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian InjuryBrain Injuries, TraumaticDemyelinating DisorderAlzheimer DiseaseNCT04710550Massachusetts General Hospital8
已完成
2 期
Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)Myelodysplastic SyndromesNCT01822691H. Lee Moffitt Cancer Center and Research Institute15
已完成
早期 1 期
18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation NecrosisSecondary Malignant Neoplasm of Brain and Cerebral MeningesNCT03930173Case Comprehensive Cancer Center18
已完成
1 期
Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1aParkinson DiseaseNCT01461083Institute for Neurodegenerative Disorders19
已完成
3 期
PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)Breast CancerNCT00201942Ontario Clinical Oncology Group (OCOG)336